surmount-1 tirzepatide Nutritional status with in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials surmount-1 tirzepatide trial obesity without

PubMed Kaux J-F, et al

doi: 10.1136/bmj.c869 Summary Keywords obesity, GLP-1, GLP-1 receptor analog, exenatide, pediatrics, glycemic control, GLP-1 receptor agonist, treatment Citation Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mrwald K, Gomahr J, Heu V, Weghuber D, Forslund A and Bergsten P (2023) Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

Tirzepatide (Mounjaro/Zepbound) : fino al 26% (SURMOUNT-1 e SURMOUNT-5)

Bring a healthy dish: Offer to bring a healthy dish to holiday gatherings or parties